Indeed, in pre-clinical models, retatrutide, a triple agonist (GLP-1/GIP/glucagon), resulted in greater WL and improved glucose profile compared to tirzepatide through increased energy expenditure and reduced calorie intake [80, 81]
Up to 25% of GLP-1 users stopped using insulin within 52 weeks of beginning GLP-1 treatment
eating more minimally processed foods higher in nutrients, fiber, and/or protein
When you take a GLP-1 medication like semaglutide (Wegovy, Ozempic) or liraglutide (Saxenda), it: Slows down how quickly food leaves your stomach, which keeps you feeling full for longer Signals to your brain that youre satisfied, reducing those constant thoughts about food and snacking Helps your pancreas release the right amount of insulin when your blood sugar rises These medications were initially developed for type 2 diabetes, which is why you might have heard of Ozempic being used off-label for weight loss